OM:CAMXPharmaceuticals
How Investors Are Reacting To Camurus (OM:CAMX) Monthly Semaglutide Data Showing Promising Obesity Results
Earlier this month, Camurus announced positive topline results from a Phase 1b trial evaluating CAM2056, its monthly FluidCrystal® semaglutide formulation, which demonstrated significant dose-dependent reductions in body weight, hemoglobin A1c, and fasting glucose in people with overweight or obesity, with efficacy comparable to or greater than weekly semaglutide.
This study suggests CAM2056 could offer similar or stronger metabolic benefits with the convenience of monthly dosing,...